 Piper Sandler has raised the price target on Integra LifeSciences Holding Corporation NASDAQ:IART to 72 from 70 and reiterated a Neutral rating following the Q2 beat. The company posted Q2 EPS of 0.79 and sales of 389.9 million, beating the consensus estimate of 0.66 and 376.0 million, respectively. 